Saniona’s CEO to BioStock: “We have meetings with potential partners every week”

Saniona is currently advancing its epilepsy assets to provide clinical proof-of-concept for SAN711 and preparing SAN2355 for phase I. Meanwhile, the company is anticipating the approval of tesofensine in Mexico this year, while scouting for yet more partnerships. BioStock spoke with the company’s CEO to learn more.
– We see interest in several of our assets and have several exciting leads to pursue. We have weekly meetings with potential partners and open data rooms for new companies every month. I’m confident that we will succeed, says Thomas Feldthus.

Read the full interview with Thomas Feldthus at biostock.se:

https://www.biostock.se/en/2024/06/sanionas-ceo-we-have-meetings-with-potential-partners-every-week/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/